These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 14746191)

  • 1. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binasal visual field defects are not specific to vigabatrin.
    Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
    Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?
    Sorri I; Brigell MG; Mályusz M; Mahlamäki E; de Meynard C; Kälviäinen R
    Epilepsy Res; 2010 Nov; 92(1):48-53. PubMed ID: 20850272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
    Hisama FM; Mattson RH; Lee HH; Felice K; Petroff OA
    Seizure; 2001 Oct; 10(7):505-7. PubMed ID: 11749107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M; Cubbidge RP; Hosking SL
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin and epilepsy: further lessons in early childhood.
    Parisi P; Bombardieri R; Curatolo P
    Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225
    [No Abstract]   [Full Text] [Related]  

  • 14. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
    Sorri I; Herrgård E; Viinikainen K; Pääkkönen A; Heinonen S; Kälviäinen R
    Epilepsy Res; 2005 Jun; 65(1-2):117-20. PubMed ID: 15941649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual fields in young children treated with vigabatrin.
    Agrawal S; Mayer DL; Hansen RM; Fulton AB
    Optom Vis Sci; 2009 Jun; 86(6):767-73. PubMed ID: 19417698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vigabatrin and epilepsy: lessons learned.
    Wild JM; Ahn HS; Baulac M; Bursztyn J; Chiron C; Gandolfo E; Safran AB; Schiefer U; Perucca E
    Epilepsia; 2007 Jul; 48(7):1318-27. PubMed ID: 17635558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
    Clayton LM; Duncan JS; Sisodiya SM; Acheson JF
    Eye (Lond); 2010 Jan; 24(1):185-6. PubMed ID: 19373265
    [No Abstract]   [Full Text] [Related]  

  • 19. [Constriction of the visual field by vigabatrin].
    Asensio Sánchez VM
    An Med Interna; 2002 Dec; 19(12):655-6. PubMed ID: 12593042
    [No Abstract]   [Full Text] [Related]  

  • 20. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
    Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
    Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.